ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Ovarian Cancer Diagnosis and Chemoresistance Prediction Model Based on cfRNA Molecular Signature.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundOvarian cancer (OVCA) is a common and highly aggressive gynecologic malignancy often diagnosed at advanced stages. Approximately 30% of patients develop platinum resistance, resulting in disease recurrence and progression. Currently, no diagnostic or chemoresistance prediction model based on plasma cell-free RNA (cfRNA) profiling exists.
methodsWe recruited 304 participants and performed plasma cfRNA sequencing. After quality control, 172 OVCA patients and 70 healthy controls were assigned to the training set, and 44 OVCA patients with 18 controls to the test set. A DenseNet-based deep learning model was developed to analyze cfRNA features.
resultsThe model distinguished OVCA patients from healthy controls with AUCs of 0.9997 in the training set and 0.9747 (95% CI: 0.9437-0.9963) in the test set. For chemoresistance prediction, it yielded AUCs of 0.9442 and 0.8421 (95% CI: 0.7504-0.9147), respectively. Our model outperformed comparative models across both tasks, though the performance advantage in the chemoresistance prediction task should be interpreted cautiously given the limited sample size. Interpretability analyses combined with bioinformatics identified FLOT1, IFITM3, and IFITM2 as putative diagnostic cfRNA biomarkers.
conclusionThis plasma cfRNA-based deep learning model identifies OVCA patients and predicts chemoresistance, offering a non-invasive tool for early diagnosis and treatment stratification.
trial registrationThis study was registered in the Chinese Clinical Trial Registry under registration number ChiCTR2500099940.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.